Literature DB >> 20547208

Roles of adenosine receptor subtypes on the antinociceptive effect of sildenafil in rat spinal cord.

Hyung Gon Lee1, Woong Mo Kim, Jeong Il Choi, Myung Ha Yoon.   

Abstract

We recently found that the antinociceptive effects produced by intrathecal administration of sildenafil, a phosphodiesterase 5 inhibitor, were reversed by a nonspecific adenosine receptor antagonist, suggesting that adenosine receptors are involved in sildenafil-induced antinociception. Four adenosine receptor subtypes have been identified: A(1), A(2A), A(2B), and A(3). We examined the involvement of spinal adenosine receptor subtypes in the antinociceptive effects of intrathecal sildenafil. Intrathecal catheters were implanted in male SD rats, and nociception was assessed using the formalin test, which consisted of a subcutaneous injection of 50 microl of 5% formalin solution into the hind paw. We examined the effects of an adenosine A(1) receptor antagonist (CPT), an adenosine A(2A) receptor antagonist (CSC), an adenosine A(2B) receptor antagonist (alloxazine), and an adenosine A(3) receptor antagonist (MRS 1220) on sildenafil-induced antinociception. Intrathecal sildenafil suppressed formalin-induced flinching during phases 1 and 2 of the test in a dose-dependent manner. Intrathecal CPT, CSC, alloxazine, and MRS 1220 all suppressed the antinociceptive effects of sildenafil during both phases of the formalin test. These results suggest that sildenafil is an effective treatment for acute pain and the facilitated pain state at the spinal level. Additionally, spinal adenosine A(1), A(2A), A(2B), and A(3) receptors may play a role in sildenafil-induced antinociception. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20547208     DOI: 10.1016/j.neulet.2010.06.025

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  3 in total

Review 1.  Drug repositioning: playing dirty to kill pain.

Authors:  Leandro Francisco Silva Bastos; Márcio Matos Coelho
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

2.  Improvement of peripheral artery disease with Sildenafil and Bosentan combined therapy in a patient with limited cutaneous systemic sclerosis: A case report.

Authors:  Loukman Omarjee; Cedric Fontaine; Guillaume Mahe; Vincent Jaquinandi
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

3.  Nonrevascularizable buttock claudication improved with Sildenafil: A case report.

Authors:  Loukman Omarjee; Audrey Camarzana; Samir Henni; Pierre Abraham
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.